Targeted Protein Degradation: The Next Frontier in Drugging the 'Undruggable'
核心洞察
Targeted protein degradation (TPD) represents a paradigm shift from occupancy-driven inhibition to event-driven protein elimination, potentially addressing historically "undruggable" targets.
Bristol Myers Squibb (搜索) is advancing multiple TPD modalities, including CELMoD molecular glues and ligand-directed degraders (LDDs), to match the mechanistic diversity of cancer.
Degrader-antibody conjugates (DACs) are emerging as a novel approach combining antibody-guided tumor targeting with protein degrader payloads for enhanced precision.
The growing understanding of cancer biology has revealed an uncomfortable truth: knowing what drives a tumor does not automatically translate into being able to stop it. Many of the most important disease-driving proteins have remained beyond the reach of conventional drugs, lacking the accessible binding pockets that traditional small-molecule inhibitors require. Now, a fundamentally different strategy — targeted protein degradation (TPD) — is reshaping what may be possible, offering a way to eliminate these proteins entirely rather than merely inhibiting them.
This shift from occupancy-driven pharmacology to event-driven protein removal reflects a broader evolution in oncology research, one that Bristol Myers Squibb (搜索) is pursuing across multiple modalities in its pipeline.
Beyond inhibition: the logic of protein degradation
Conventional cancer drugs typically work through an occupancy-driven approach: a drug binds to a disease-causing protein and inhibits its activity, interrupting a pathway that helps cancer cells survive or grow. While these approaches have transformed care, they carry inherent limitations. Some proteins lack accessible binding sites altogether. Others may continue signaling through alternate pathways. In many cases, cancer cells develop resistance, rendering an initially effective treatment ineffective over time.
Targeted protein degradation addresses these challenges by leveraging the cell's own protein disposal machinery — the ubiquitin-proteasome system — to selectively tag and remove disease-related proteins. Rather than requiring a drug to remain bound to maintain inhibition, degraders trigger a catalytic process that can eliminate the target protein entirely. This event-driven mechanism may broaden the range of biological targets researchers can address and offer an alternative where conventional inhibition is insufficient.
The scientific foundation for TPD was built, in part, through years of research on immunomodulatory drugs (IMiDs) used in hematology. Scientists uncovered how these therapies interact with the cell's natural protein degradation pathways, helping establish the mechanistic understanding that now supports a rapidly evolving therapeutic platform.
A multi-modal toolkit for a complex disease
Cancer is driven by mechanistic diversity, and different disease settings call for distinct scientific approaches. Bristol Myers Squibb (搜索)'s TPD research reflects this reality by advancing multiple degradation modalities rather than a single strategy.
CELMoD agents, a type of molecular glue, exemplify how growing mechanistic insights can create new therapeutic opportunities. These agents explore how altering cereblon (搜索)'s protein-binding properties may promote interactions that lead to the degradation of specific disease-related proteins.
For proteins that require a more direct binding strategy, ligand-directed degraders (LDDs) offer an alternative. These larger, three-part molecules are designed around a specific target-binding component and are engineered to link target proteins with the cell's degradation machinery, enabling their removal.
Each modality offers distinct scientific advantages and may be better suited to specific biological mechanisms, disease settings, and treatment strategies. Together, they demonstrate the versatility of TPD and complement the broader range of oncology approaches being explored.
The next evolution: degrader-antibody conjugates
After early protein degraders demonstrated that disease-driving proteins could be selectively removed, a new question emerged: how could that capability be directed with greater precision? One emerging area of investigation draws on lessons from antibody-drug conjugates: degrader-antibody conjugates (DACs), which pair antibody-guided targeting with a protein degrader payload.
DACs are being explored as a way to direct TPD toward tumors in settings where precise delivery may be important to driving potency. This approach illustrates how oncology innovation often builds by combining findings across fields — biology, chemistry, engineering, and computational science — to design approaches that better meet the complexity of cancer.
AI accelerates discovery
Advances in artificial intelligence and machine learning are helping accelerate TPD discovery. Researchers can now analyze increasingly complex biological datasets, model molecular interactions, and identify promising opportunities more efficiently than ever before. These technologies are helping scientists generate stronger hypotheses and move more quickly from biological understanding to therapeutic design.
Together, these advances — from a clearer view of disease mechanisms to AI-enabled discovery — are helping advance TPD across oncology, malignant and non-malignant hematology, and potentially other therapeutic areas including neuroscience and immunology.
A future built on connected insights
The history of cancer research is a story of continually expanding knowledge and evolving ways to act on it. Targets once considered difficult to address are becoming active areas of investigation. The convergence of scientific innovations is opening new avenues for exploration, helping researchers pursue disease-driving mechanisms that have previously been difficult to drug.
Targeted protein degradation is one example of this shift. As part of Bristol Myers Squibb (搜索)'s broader oncology research, it reflects a larger effort to address the biological diversity of cancer through a wider range of therapeutic approaches. The future of cancer research will not be defined by a single discovery, but by the ability to connect deeper biological insights and translate that understanding into more meaningful outcomes for patients.